To be clear, GLP-1s are not FDA-approved for treating these conditions right now, but if more research proves they are safe and effective, they could receive formal approval for these uses (or others) in the future
This slows down your metabolism, causes fluid retention, increases fat storage, and makes it extremely difficult to lose weight even with calorie restriction and workouts
Allosteric (off active site) activators were reported in the literature as early as the mid-2000s, but they had poor potency, poor pharmacokinetics, species-selective activity (human but not rodent), and none made it close to the clinic
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist mimicking the natural GLP-1 hormone in appetite regulation
Researchers are exploring how semaglutide, a medication for diabetes and weight loss, may affect chronic kidney disease